Zomedica Pharmaceuticals logo

ZOM - Zomedica Pharmaceuticals Share Price

C$0.5 0.0  0.0%

Last Trade - 02/12/19

Sector
Healthcare
Size
Micro Cap
Market Cap £28.7m
Enterprise Value £26.8m
Revenue £n/a
Position in Universe 827th / 2611
Bullish
Bearish
Unlock ZOM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZOM Revenue Unlock ZOM Revenue

Net Income

ZOM Net Income Unlock ZOM Revenue

Normalised EPS

ZOM Normalised EPS Unlock ZOM Revenue

PE Ratio Range

ZOM PE Ratio Range Unlock ZOM Revenue

Dividend Yield Range

ZOM Dividend Yield Range Unlock ZOM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZOM EPS Forecasts Unlock ZOM Revenue
Profile Summary

Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a veterinary pharmaceutical and healthcare solutions company. The Company's principal business relates to the discovery, development and commercialization of pharmaceuticals for the companion pet. The Company's first product candidate, ZM-012, is a tablet formulation of metronidazole, an anti-infective for the treatment of diarrhea in canines (dogs). The Company's second product candidate, ZM-006, is a transdermal gel that delivers its active pharmaceutical ingredient, methimazole, which is used in veterinary medicine to treat hyperthyroidism in felines (cats). The Company's third product candidate, ZM-007, is an oral suspension formulation of metronidazole for accurate dosing of small dog breeds and puppies. The Company's fourth product candidate, ZM-011 is a transdermal gel of fluoxetine, Prozac, prescribed to treat cat behavioral disorders, such as inappropriate urination.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 7, 2013
Public Since October 28, 2013
No. of Shareholders: n/a
No. of Employees: 27
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange TSX Venture Exchange
Shares in Issue 108,038,398
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZOM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to ZOM
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.